Replies to post #62852 on Avid Bioservices Inc (CDMO)

[alvaroc2]

Good news, important to break 2.78 swag 100ss in a weekend analisis and 2.87 tendency of medium term, good luck!!!.

[pphmtoolong]

Bavi plays well with others. So, it doesn't threaten the current SOC pharma. Bavi's adoption will not be limited by competitors protecting their turf. In fact it makes the current SOC drugs look even better. If Bavi continues to pan out in the trials, some smart pharma may make a lot of money selling it.

Paul

[jessme]

I believe we had great results in bavi animal studies with viral also yet the government didn't renew our grant.
We've always had great results in animal studies for various diseases. 1 in 5000 make it from the lab to FDA approval. Yesterday's PR included actual human data and we ended up a penny. How is tha actual human trial doing?
Will we maintain today's spike or give it back?


Peregrine's PS-Targeting Antibody Significantly Improves Anti-Tumor Effect of Sorafenib in Models of Advanced Liver Cancer


As presented today at AACR, tumor growth was 69% less for the group receiving Peregrine's antibody in combination with sorafenib than for the group receiving sorafenib alone (mean tumor weight of 127 mg versus 409 mg, n=10, p < 0.01) after 59 days of treatment in an animal model study.